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Abstract The excitatory neurotransmitter glutamate plays a
major role in determining certain neurological disorders. This
situation, referred to as ‘glutamate neurotoxicity’ (GNT), is
characterized by an increasing damage of cell components,
including mitochondria, leading to cell death. In the death
process, reactive oxygen species (ROS) are generated. The
present study describes the state of art in the field of GNT with a
special emphasis on the oxidative stress and mitochondria. In
particular, we report how ROS are generated and how they
affect mitochondrial function in GNT. The relationship between
ROS generation and cytochrome c release is described in detail,
with the released cytochrome c playing a role in the cell defense
mechanism against neurotoxicity. ß 2001 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
In the last three decades, the excitatory neurotransmitter
glutamate has been shown to cause certain neurological dis-
eases [1^3]. This situation, referred to as ‘glutamate neurotox-
icity’ (GNT), is characterized by time-dependent damage of
many cell components leading to cell death. In the biochem-
ical processes leading to cell death, reactive oxygen species
(ROS), i.e. superoxide anion (O32 ), hydroxyl radical (OH
)
and hydrogen peroxide (H2O2), are generated in di¡erent cell
compartments due to several reactions. However, cells can
prevent ROS damage in virtue of the presence of a variety
of molecules that work as antioxidants. Moreover, signi¢cant
processes occur due to the presence of ion channels [4] and
other reactions including S-nitrosation, thiolation and cate-
cholamine oxidation (for references see [5]).
At present, exactly how cell death due to neurotoxicity
occurs is rather obscure. In particular, ROS sources, scav-
engers and mechanisms of action remain to be fully estab-
lished. In the present study, these issues are considered with
a special emphasis on oxidative stress and mitochondria.
These organelles are responsible for biological oxidations:
they can produce ROS and are subjected to oxidative stress
with a severe impairment of their functions including cell en-
ergy supply and metabolite transport [6^8].
2. ROS production in brain
A consensus has been achieved on the conclusion that GNT
takes place as a result of glutamate binding to the N-methyl-
D-aspartic acid (NMDA) receptor and to a minor extent to
other receptor subtypes and that it depends on neuronal Ca2
overloading (for references see [1,9]). Brie£y, GNT is caused
by glutamate binding to its receptor/s. This involves essen-
tially two components. The ¢rst component marked by acute
neuronal swelling, depends on the uptake of extracellular Na
and Cl3 uptake by the cell that causes plasma membrane
depolarization; this causes Ca2 channel opening that triggers
the second component that is marked by delayed neuronal
degeneration. In this case, the massive in£ux of extracellular
Ca2, together with any Ca2 release triggered from intracel-
lular stores, increases cytosolic free Ca2 and initiates a cas-
cade-like e¡ect leading to cell death. It should be noted that,
in a Na^Ca2-free medium, NMDA receptor-mediated K
e¥ux may contribute to neuronal apoptosis [10].
The elucidation of the variety of events occurring down-
stream of neuronal Ca2 overloading is still a matter for fur-
ther research. As far as mitochondria are concerned, it has
been reported that they accumulate Ca2 (for references see
[9]). On the other hand, ROS generation undoubtedly takes
place in GNT [11^15] and is likely due to Ca2 in£ux in the
cytosol ; consistently both (+)-5-methyl-10,1-dihydro-5H-di-
benzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK801),
a selective NMDA receptor antagonist, and EGTA, which can
remove calcium ion, were shown to prevent ROS production
as well as cell death [13]. Thus, in spite of the occurrence of
many cell defense mechanisms against ROS, widely di¡used in
the liver but relatively de¢cient in the brain [16], in GNT a
condition of ‘oxidative stress’ can develop (for references see
[17]).
One of the most outstanding problems to be considered
when studying the role of ROS production in neurotoxicity
is the dependence of ROS formation on the time after gluta-
mate exposure; indeed, ROS can be produced according to a
variety of mechanisms and manifest di¡erent e¡ects in a time-
dependent manner.
The ¢rst suggestion of a causal relationship between GNT
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and ROS production was proposed by Dykens et al. [18] who
observed that neuron damage caused by the excitotoxin kai-
nate is prevented by both superoxide dismutase that can re-
move O32 and by mannitol, used as an OH
 scavenger. In
other studies, cortical and/or cerebellar neuron damage pre-
vention was also found when using other antioxidants includ-
ing K-tocopherol, ascorbic acid, ubiquinone, or 21-amino ste-
roids [19,20]; conversely, the depletion of the antioxidant
glutathione was found to exacerbate toxicity [21]. In a di¡er-
ent experimental approach, cultured cortical neurons from
mice over-expressing the free radical scavenging enzyme
superoxide dismutase were found to be resistant to glutamate
toxicity and showed the involvement of glutathione in neuro-
degeneration (for references see [22]). Finally, electron para-
magnetic resonance spectroscopy provided direct evidence
that NMDA receptor activation leads to the generation of
superoxide radicals [11]. Shulz et al. provided the ¢rst in
vivo evidence that excitotoxic neuronal injury is linked to
free radical generation and showed the involvement of gluta-
thione in neurodegeneration (for references see [23]).
Interestingly, Alzheimer’s disease also involves free radical
accumulation [24].
Some aspects of the processes leading to ROS production
have been investigated in detail. Xanthine oxidase (XOD) was
proposed as ROS producer [25] as allopurinol, an inhibitor of
this enzyme, was found to prevent ROS production. It was
suggested that Ca2-induced activation of one member of the
cysteine proteases converts xanthine dehydrogenase (XDH)
into XOD thus allowing for H2O2 and O32 production
[1,18]. Surprisingly, no XDH/XOD activity has been detected
in neurons [18,26], until Atlante et al. [13], taking advantage
of a modi¢ed XOD assay [27], showed that XOD activity,
derived from XDH via an enzymatic cleavage [18,28,29], can
produce O32 at the beginning of GNT.
Beside the XOD-dependent ROS production, in the brain
the presence of ROS is due to mitochondrial electron £ow via
the respiratory chain [6,7,30,31] with a di¡erent individual
contribution depending on the di¡erent types of cells inves-
tigated and di¡erent experimental conditions used. The ROS
production by mitochondria could derive from electron leak-
ing from the transport chain to oxygen at high potential sites
[6,30^32]. Moreover, defects in electron transport complexes
or other perturbations of mitochondria can be responsible for
excess production of ROS leading to glutamate toxicity
[31,33^36]. A strong indication of the mitochondrial ROS
generation in neurotoxicity derives from the evidence that
the enhanced cellular O32 production in the presence of glu-
tamate is abolished by rotenone/oligomycin [14]. It should be
noted that, in this case, ROS production was measured over a
relatively long period of time, i.e. about 1 h after beginning
glutamate treatment.
According to Choi [1], arachidonic acid metabolism by ox-
idases could lead to the production of oxygen free radicals
that can trigger peroxidative degradation of lipid membranes
and other destructive events [37]. Interestingly arachidonic
acid and ROS were found to inhibit glutamate uptake in
astrocytes via two distinct and additive mechanisms [38].
Ciani et al. [39] demonstrated that phospholipase A2 and
nitric oxide synthase activated by Ca2 in£ux in the cell give
rise to ROS whose deleterious action can be counteracted
either by inhibiting these enzymes or by scavenging the excess
of free radicals produced by them.
3. Mechanism of ROS action
ROS reactivity with DNA, proteins and lipids makes it easy
to blame them for a variety of pathologies including GNT.
Since mitochondria per se are vulnerable targets of ROS
[7,40,41], one could conclude that initial ROS production
could reduce mitochondrial respiration, with mitochondrial
damage becoming acute due to ROS-induced alterations in
mitochondrial DNA, proteins or lipids. However, these events
are considered to occur over a relatively long time. The under-
standing of the mechanism of ROS action could take advan-
tage of experimental work aimed at establishing the time
course of the investigated process. In this respect, we have
investigated the relationship between both mitochondrial
ROS production and release of cytochrome c (cyt c) in the
early phase (up to 30 min) of GNT [42]: cyt c release takes
place owing to the ROS generation both in glutamate-treated
cerebellar granule cells and in sister control cultures incubated
in the presence of a ROS generating system. The released cyt c
can work as a ROS scavenger and electron donor to the
respiratory chain. Interestingly, cyt c release was found to
occur in cerebellar granule cells from mitochondria that
were essentially coupled and intact and that had a negligible
production of oxygen free radicals. In agreement with [14,35],
mitochondria from cells treated with glutamate for 3 h were
mostly uncoupled and produced ROS at a high rate. The
cytosolic fraction containing the released cyt c was able to
transfer electrons from superoxide anion to molecular oxygen
via the respiratory chain and was found to partially prevent
glutamate toxicity when added externally to cerebellar neu-
rons undergoing necrosis. These ¢ndings con¢rm Skulachev’s
proposal that cyt c can work as an antioxidant, derived from
experiments carried out in a heterologous system [43,44], and
has the added dimension that cyt c release is shown in vitro to
be part of a cellular and mitochondrial defense mechanism
against oxidative stress in the early phase of neurotoxicity.
A comparison made between mitochondrial function, as
investigated in cell homogenate, and cell viability in 3 h
GNT [42] shows that in this time during ROS production,
the cells appear to be essentially intact, whereas mitochondria
are already damaged, as shown by the decrease in both res-
piration and ATP synthesis [35,42]. Glucose oxidation was
investigated with respect to both the electron £ow via respi-
ratory chain and the mitochondrial shuttles. In both cases a
signi¢cant impairment was found [35,45]. However, as a result
of cyt c release, an increase of the oxidation of externally
added NADH was found, probably occurring via the mito-
chondrial NADH-b5-oxidoreductase [45,46]. Consistently, ac-
tivation in lactate production and plasma membrane NADH-
oxidoreductase activity was found in glutamate-treated cells.
It should be noted that no signi¢cant release of both inter-
membrane space and matrix enzymes was found under the
same conditions [45], showing that in this process no mem-
brane permeability transition (MPT) takes place (see [47]).
The picture emerging from these results and from [14,34,
48^50] (Fig. 1) is that there are two phases of ROS formation
after exposure to glutamate: an early ROS production
coupled to XOD activation, and perhaps to other as yet un-
identi¢ed processes, and a later ROS production mostly due
to mitochondria. Long glutamate treatment results in perma-
nent damage of mitochondria and large uncoupling, which
occurs simultaneously with high mitochondrial ROS produc-
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tion. In this case, cytosolic Ca2 deregulation is followed by
MPT [9,51]. However, although this may provide an attractive
unifying hypothesis, particularly since oxidative stress facili-
tates the opening of the transition pore, it would caution
against an apparent consensus [52,53] that the MPT, observed
with isolated mitochondria, occurs in intact cells as a compo-
nent of necrotic neuronal cell death. Interestingly the induc-
tion of a non-speci¢c permeability transition pore in the inner
Fig. 1. The GNT time course. The time course of GNT is described as occurring in two phases. (1) Early phase (up to 30 min): 1.1, glutamate
binding to receptor; 1.2, calcium in£ux in cytosol; 1.3, XDHCXOD conversion; 1.4, ROS production; 1.5, ROS-induced cyt c release; 1.6,
Cyt c as ROS scavenger; 1.7, Cyt c as electron donor; 1.8, Cyt c-dependent energy generation. (2) Later phase (3^24 h): 2.1, glucose uptake in-
crease; 2.2, increase in lactate production via glycolysis; 2.3, mitochondrial shuttle impairment; 2.4, NADH oxidation via mitochondrial
NADH-b5-oxidoreductase; 2.5, massive ROS production by mitochondria; 2.6, mitochondrial permeability transition. Abbreviations used: Cyt
c, cytochrome c ; DHAP, dihydroxyaceton-phosphate; G3P, glycerol-3-phosphate; GLU, glutamate; GNT, glutamate neurotoxicity; MAL, ma-
late; MK801, (+)-5-methyl-10,1-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate; MPT, mitochondrial permeability transition;
H2O2, hydrogen peroxide; O32 , superoxide anion;
OH, hydroxyl anion; OAA, oxaloacetate; PFK, phosphofructokinase; ROS, reactive oxy-
gen species; XDH, xanthine dehydrogenase; XOD, xanthine oxidase.
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mitochondrial membrane was suggested as a ¢rst step in mi-
tochondrial destruction [54,55]. Such a suggestion was based
on the failure of mitochondria to sequestrate rhodamine 123.
Since this process is accompanied by ultrastructural altera-
tions in a granule cell, including clumping of the chromatin,
swelling of the endoplasmic reticulum and mitochondria and
disruption of the mitochondrial cristae, we could consider
these events to occur in the later phase of neurotoxicity.
In agreement with [13,42], Luetjens et al. [50] demonstrated
that the delayed superoxide production in excitotoxicity as
well as in apoptosis, occurs secondary to a defect in mitochon-
drial electron transport and that mitochondrial cyt c release
occurs upstream of this defect.
We conclude that in the early phase of GNT the non-mi-
tochondrial ROS production triggers a cell defense mecha-
nism in which a protective role is exhibited by cyt c released
owing to ROS production. In the later phases of neurotoxicity
ROS production is a result of cell dysfunction leading to cell
death in a process in which mitochondrial damage, that oc-
curs as a self-propagating process [41], could be considered
one of the most relevant causes both in ROS production and
in cell impairment [56]. In particular, local damage could im-
pair mitochondrial energy production [15,40,42,52], enhancing
depletion of cellular energy stores, and leading to the impair-
ment of certain homeostatic or protective mechanisms [24].
There are other ROS cell targets including phosphofructo-
kinase (PFK), creatine phosphokinase, and lactate dehydro-
genase that are susceptible to oxidative inactivation. In this
context it should be noted that the activities of several en-
zymes susceptible to oxidative inactivation, including PFK,
are reportedly reduced in post-mortem brain from Alzheim-
er’s disease patients and in gerbil brain after ischemia^reper-
fusion [57].
In addition, the increasing ROS production is expected to
deplete cellular antioxidant defenses, leading to a general en-
hancement of oxidative stress and radical-mediated injury
throughout the cell [39], this being the ¢nal factor in the
cascade of events leading to neuronal injury after excitotoxic
NMDA receptor activation [11,34].
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